देश: कनाडा
भाषा: अंग्रेज़ी
स्रोत: Health Canada
GLICLAZIDE
MINT PHARMACEUTICALS INC
A10BB09
GLICLAZIDE
60MG
TABLET (EXTENDED-RELEASE)
GLICLAZIDE 60MG
ORAL
30/60
Prescription
SULFONYLUREAS
Active ingredient group (AIG) number: 0119934003; AHFS:
APPROVED
2015-04-07
_ Page 1 of 41 _ PRODUCT MONOGRAPH PR MINT-GLICLAZIDE MR GLICLAZIDE MODIFIED-RELEASE TABLETS 30 MG MODIFIED-RELEASE BREAKABLE TABLETS 60 MG Hypoglycemic sulfonylurea Oral antidiabetic agent MINT PHARMACEUTICALS INC. 6575 Davand Drive Mississauga, Ontario L5T 2M3 Submission Control No: 234824 Date of Revision: February 21, 2020 _ Page 2 of 41 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION .............................................................. 3 SUMMARY PRODUCT INFORMATION ............................................................................... 3 INDICATIONS AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS ........................................................................................................... 4 WARNINGS AND PRECAUTIONS ......................................................................................... 4 ADVERSE REACTIONS ........................................................................................................... 8 DRUG INTERACTIONS ......................................................................................................... 13 DOSAGE AND ADMINISTRATION ..................................................................................... 16 OVERDOSAGE ........................................................................................................................ 18 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 18 STORAGE AND STABILITY ................................................................................................. 22 SPECIAL HANDLING INSTRUCTIONS ............................................................................... 22 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................................... 22 PART II: SCIENTIFIC INFORMATION ....................................................................................... 23 PHARMACEUTICAL INFORMATION ............... पूरा दस्तावेज़ पढ़ें